Homepage
Author:
CO-DIAGNOSTICS
Posted Date:
May 19, 2026
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
CO-DIAGNOSTICS
May 19, 2026
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
CO-DIAGNOSTICS
May 19, 2026
Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia’s Sudair Industrial City
CO-DIAGNOSTICS
May 8, 2026
Co-Diagnostics Announces First Quarter 2026 Earnings Release Date and Webcast
CO-DIAGNOSTICS
April 30, 2026
Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C.
CO-DIAGNOSTICS
April 16, 2026
Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany
CO-DIAGNOSTICS
April 14, 2026
Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah
CO-DIAGNOSTICS
April 9, 2026
Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia’s Sudair Industrial City
CO-DIAGNOSTICS
April 2, 2026
Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization
CO-DIAGNOSTICS
March 25, 2026
Co-Diagnostics Signs Agreement to Significantly Expand Commercial and Distribution Territory Across South Asia
CO-DIAGNOSTICS
March 20, 2026
1
2
Next
